Kaposi Sarcoma Treatment Market Forecast 2020-2025
By 2019, the Kaposi Sarcoma Treatment market will be worth $122.4 million, and it is expected to increase at a CAGR of 4.12% from 2020 to 2025. The increased incidence of cancer is causing the Kaposi Sarcoma Treatment market to rise at a rapid pace. Kaposi sarcoma (KS) is a cancer that arises from cells that line lymphatic or blood arteries. KS aberrant cells produce purple, red, or brown patches or tumours on the skin called as lesions. As, Because Kaposi sarcoma is easily contracted by a body with a weakened immune system, the likelihood of Kaposi sarcoma incidence rises, fueling the market's expansion. Improvements in drug resistance, failure rate, side effects, and case-fatality ratios, as well as an increasing emphasis on combination therapy, are expected to move the Kaposi Sarcoma Treatment market during the forecast period 2020-2025.
Key Takeaways
- In
the year 2019, North America dominated the Kaposi Sarcoma Treatment market
with a 38 percent share.
- Rising
research and development activity in this industry, technical
developments, increased mergers and acquisitions, and strategic
cooperation are some of the primary factors expected to drive the Kaposi
Sarcoma Treatment market forward.
- Increased demand for food and beverage items
with a longer shelf life, minor nutritional changes in products like milk,
and lower logistics and storage costs are the main reasons driving the
segment's growth between 2020 and 2025.
By Treatment - Segment Analysis
Due to the increased incidence rate of
AIDS-associated Kaposi sarcoma over other varieties, the Antiretroviral Therapy
(HAART) category had the greatest proportion of the market. In addition, there
has been an increase in demand for this treatment, and the high cost of
treatment is expected to drive market expansion. Furthermore, for persons with
epidemic Kaposi sarcoma, antiretroviral therapy (ART) for HIV/AIDS is normally
given first, before any other treatments, to treat the tumour and alleviate
symptoms; nevertheless, ART can sometimes exacerbate preexisting infections and
make the Kaposi sarcoma worse. The segment is expected to increase at a 3.44
percent compound annual growth rate (CAGR).
Drivers – Kaposi Sarcoma Treatment
market
- Rising demand of patients undergoing organ
transplant procedures
Because patients undergoing organ
transplant procedures are especially susceptible to Kaposi sarcoma, the Kaposi
sarcoma therapy market has grown in tandem with the increase in demand for
organ transplant procedures.According to data released by the American Cancer
Society (ACS) in February 2016, approximately 1 in 200 transplant patients in
the United States had Kaposi sarcoma, which can be considered a Kaposi Sarcoma
key driver of the market from 2020 to 2025.
Comments
Post a Comment